The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system

BackgroundOfatumumab is a humanized monoclonal antibody that targets CD20-positive B cells. It was approved by the FDA in 2020 for the treatment of relapsing multiple sclerosis (RMS) in adult patients, and in 2009 for the treatment of Chronic Lymphocytic Leukemia (CLL). With the escalating clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: Yue Zhou, Yutong Wu, Xiao Zhao, Lingxu Xu, Mingguang Sun, Zhaoyou Meng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
ofatumumab
FAERS
MS
CLL
pharmacovigilance
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515730/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515730/full

Similar Items